Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?
Authors
Keywords
-
Journal
CANCER
Volume 123, Issue 2, Pages 200-209
Publisher
Wiley
Online
2016-11-17
DOI
10.1002/cncr.30314
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
- (2016) A. Ari Hakimi et al. CANCER CELL
- Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression
- (2016) S. A. Brooks et al. CLINICAL CANCER RESEARCH
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations
- (2016) Gabriel G. Malouf et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
- (2016) Richard W. Joseph et al. JOURNAL OF UROLOGY
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities
- (2016) Scott M. Haake et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
- (2015) A. Ravaud et al. ANNALS OF ONCOLOGY
- Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
- (2015) M. Dror Michaelson et al. CANCER
- Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron
- (2015) Florian Büttner et al. EUROPEAN UROLOGY
- Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
- (2015) Brian Shuch et al. EUROPEAN UROLOGY
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- (2015) Amanda J. Redig et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
- (2014) Caleb F. Davis et al. CANCER CELL
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
- (2014) David F. McDermott et al. CLINICAL CANCER RESEARCH
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
- (2014) Samira A. Brooks et al. EUROPEAN UROLOGY
- Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer--Targeting the Warburg Effect in Cancer
- (2013) W. M. Linehan et al. CLINICAL CANCER RESEARCH
- Collecting Duct Carcinomas Represent a Unique Tumor Entity Based on Genetic Alterations
- (2013) Frank Becker et al. PLoS One
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma
- (2012) Nizar M. Tannir et al. EUROPEAN UROLOGY
- SMARCB1/INI1 inactivation in renal medullary carcinoma
- (2012) Julien Calderaro et al. HISTOPATHOLOGY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- The VHL/HIF axis in clear cell renal carcinoma
- (2012) Chuan Shen et al. SEMINARS IN CANCER BIOLOGY
- Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma
- (2010) Toni K. Choueiri et al. CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
- (2008) John D. Gordan et al. CANCER CELL
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
- (2008) M. L. Nickerson et al. CLINICAL CANCER RESEARCH
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- (2007) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started